BioSpace News Archive

CytoDyn will file an IND, along with a proof-of-concept protocol for colon cancer

Officials from Health Canada will hold a technical briefing to discuss the proposed special review decisions for thiamethoxam and clothianadin.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2018.

The Patient Safety Authority has released a new Request for Proposals (RFP) to provide clinical analysis for its Pennsylvania Patient Safety Reporting System (PA-PSRS) data.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd(Kyowa Hakko Kirin), and Kyowa Kirin International PLC today announced that the Phase 3 study of Crysvita® (burosumab) met its primary endpoint.

Playgrounds are a fun place for kids to let loose and get their daily dose of exercise. Exercise is essential to a child’s development as it helps them maintain a healthy body weight and build strong bones and muscles. However, if playground equipment is not properly used and maintained, injuries can occur.

ltragenyx Pharmaceutical Inc.(NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 7, 2018 at 5pm ET to discuss first quarter 2018 financial results and provide a corporate update.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC today announced that Crysvita® (burosumab-twza) entered the commercial supply chain in the United States and generated its first sales to specialty pharmacies on April 27, 2018.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with IsCann Group Limited (“IsCann”) located in Be’er Tuvya, Israel